# Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)

> **NCT02493764** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 537 (actual)

## Conditions studied

- Bacterial Pneumonia

## Interventions

- **DRUG:** Imipenem
- **DRUG:** Relebactam
- **DRUG:** Cilastatin
- **DRUG:** Piperacillin
- **DRUG:** Tazobactam
- **DRUG:** Linezolid

## Key facts

- **NCT ID:** NCT02493764
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-24
- **Primary completion:** 2019-04-03
- **Final completion:** 2019-04-03
- **Target enrollment:** 537 (ACTUAL)
- **Last updated:** 2020-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02493764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02493764, "Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT02493764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*